Cite
HARVARD Citation
Coens, C. et al. (n.d.). Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial. Lancet oncology. 18 (3), pp. 393-403. [Online].